Home / Market News / $TWST
fiscal.ai Corporate Catalyst Impact 65/100 ● negative

Guggenheim Lowers Price Target on Twist Bioscience

Nov 13, 2026, 12:35 PM UTC · Primary ticker $TWST

Guggenheim has lowered its price target for Twist Bioscience (TWST) from $212 to $150. This significant reduction by a prominent analyst firm indicates a revised, less optimistic valuation of the company, likely leading to negative short-term market sentiment for TWST.

Guggenheim, a notable financial institution, has significantly reduced its price target for Twist Bioscience (TWST) from $212 to $150. This action signals a material shift in the firm's valuation of the synthetic biology company, suggesting a less favorable outlook on its future prospects or current performance. For traders, this is a negative signal in the short term, as analyst downgrades often lead to selling pressure and a decline in stock price. While not a fundamental change in the company's operations, it reflects a change in expert perception, which can influence investor confidence and potentially impact the stock's trajectory until new catalysts emerge. The key risk for traders is further downside if other analysts follow suit or if the market interprets this as a sign of underlying issues not yet fully priced in.

$TWST negative Analyst price target downgrade
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.